Werkgroep Cardiologische centra Nederland English

PARAGON (Follow up)

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.

Middel
LCZ696
Populatie
hartfalen
Fase
III
Jaar aanvang
2013
Meer informatie
ClinicalTrials.gov

Studiedirecteur

dr. G.C.M. Linssen (Cardioloog)
Almelo, ZGT

PARAGON: Nieuws